Liver & Intestine Transplant Perspective

 
 
  • Hepatitis C Therapies Perform Well in Challenging Patients This year's Digestive Disease Week focused on shorter, simpler treatments, and new ways to predict outcome. Dr William Balistreri shares the results.
  • 10 Key Primary Care Takeaways: DDW 2017   The 'really hot stuff' from this year's Digestive Disease Week that will interest primary care providers, according to Dr David Johnson.
  • Cirrhosis Paradox: Is the Risk for Clotting or for Bleeding?   Previously thought to be 'anticoagulated,' patients with cirrhosis really might be hypercoagulable. Dr David Johnson explains why this paradox is a 'must understand' for all who manage this condition.
  • New Insights Into Liver Disease and Transplantation Findings on new therapeutic options, long-term outcomes, and diagnostic tools were on view at the recent Liver Meeting. Dr William Balistreri reports what you need to know most.
  • Liver Disease and the Gut Microbiome What role does the gut microbiome play in the development of liver injury and end-stage liver disease?
  • New Drugs Seek to Further Improve Outcomes in Hepatitis C At the recent Liver Meeting, the spotlight was on next-generation interferon- and ribavirin-free regimens. Dr William Balistreri highlights the most interesting results.
  • Is It Covert or Overt Hepatic Encephalopathy? Hepatic encephalopathy manifests as a wide spectrum of abnormalities, ranging from subclinical alterations to coma. Careful testing, diagnosis, and treatment are required.
  • Portal Vein Thrombosis: Early Recognition, Improved Outcomes Although rare in the general populace, portal vein thrombosis can present secondary to various liver diseases and infections.
  • New Data Shine a Light on Liver Disease A roundup of the most impactful research on nonalcoholic fatty liver disease, chronic cholestatic liver diseases, and hepatotoxicity, as presented at this year's Digestive Disease Week.
  • Hepatitis C: Let's Get 'Real' Clinical trials have shown that current treatment approaches for hepatitis C are highly successful. Can this degree of success be attained in real-world populations?
  • A Simultaneous Liver-Kidney Transplant? Not So Fast   Do you really need that kidney first? Drs Berns and Reese discuss UNOS' new rules for kidney transplantation in liver transplant recipients.
  • New Data May Soon Reshape Transplantation Decisions in ESLD Dr William Balistreri provides an overview of the research that's adding compelling new ideas on how to enhance transplantation protocols for all types of patients.
  • Progress Noted in Treatment of Several Common Liver Diseases Dr William Balistreri provides an overview of the latest data on such disorders as alpha-1 antitrypsin deficiency, drug-induced liver injury, and parenteral nutrition-associated cholestasis.
  • Surveying the Latest Data in Fatty Liver Disease The recent Liver Meeting featured a wealth of studies on nonalcoholic fatty liver disease and steatohepatitis. Dr William Balistreri shines a light on those most likely to affect your practice.
  • A Focus on Hepatitis C: Outcomes Dr William Balistreri completes his three-part series on hepatitis C with a discussion about possible outcomes and a glimpse into the future of treatment.
  • A Focus on Hepatitis C: Novel Therapeutic Regimens In the second part of this three-part series, Dr William Balistreri continues his discussion of hepatitis C with a review of new antiviral agents and novel therapeutic strategies.
  • Liver Before Heart: Reversing Combined Organ Transplantation   Drs Sudhir Kushwaha and Rocky Daly share their considerations in reverse-order heart-liver transplant cases at Mayo's Heart Transplant Clinic.
  • A Focus on Hepatitis C: Cascade of Care In the first part of this three-part series on hepatitis C, Dr William Balistreri discusses the prevalence of this infection, screening methods, and access and barriers to care.
  • Treating CDI: Fresh or Frozen Feces?   Dr Lundberg describes a recent study of fecal microbiota transplantation for CDI and applauds the lack of FDA interference.
  • Sirolimus to Prevent Vasculopathy after Heart Transplant   Dr Sudhir Kushwaha describes vasculopathy following heart transplants and gives the lowdown on sirolimus-based immunosuppression.